FOXO3-induced oncogenic lncRNA CASC9 enhances gefitinib resistance of non-small-cell lung cancer through feedback loop

Long Noncoding RNA LINC00460 Promotes the Gefitinib Resistance of Nonsmall Cell Lung Cancer Through Epidermal Growth Factor Receptor by Sponging miR-769-5p

(2019) Guodong Ma et al.   DNA AND CELL BIOLOGY

MiRNA-195-5p Functions as a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

(2019) Jing Zheng et al.   PATHOLOGY & ONCOLOGY RESEARCH

New Insights into Long Non-Coding RNA MALAT1 in Cancer and Metastasis

(2019) Yutong Sun et al.   Cancers

Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis

(2019) Adrian D. Vickers et al.   BMC CANCER

Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer

(2019) Gugnoni et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The effects and the mechanisms of autophagy on the cancer-associated fibroblasts in cancer

(2019) Yuanliang Yan et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment

(2019) Narjust Duma et al.   MAYO CLINIC PROCEEDINGS

ncRNA-Encoded Peptides or Proteins and Cancer

(2019) Jizhong Wang et al.   MOLECULAR THERAPY

LncRNA UCA1 promotes gefitinib resistance as a ceRNA to target FOSL2 by sponging miR-143 in non-small cell lung cancer

(2019) Xiliu Chen et al.   Molecular Therapy-Nucleic Acids

LncRNA HOXA-AS3 confers cisplatin resistance by interacting with HOXA3 in non-small-cell lung carcinoma cells

(2019) Shuang Lin et al.   Oncogenesis

The lncRNA RHPN1-AS1 downregulation promotes gefitinib resistance by targeting miR-299-3p/TNFSF12 pathway in NSCLC

(2018) Xuehao Li et al.   CELL CYCLE

miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT

(2018) Demin Jiao et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Clinicopathological implications of MET exon 14 mutations in non-small cell lung cancer – A systematic review and meta-analysis

(2018) Huy Gia Vuong et al.   LUNG CANCER

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3

(2018) Jinnan Yue et al.   ONCOGENE

Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation

(2018) James Chih-Hsin Yang et al.   Journal of Thoracic Oncology

Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis

(2017) Zuyao Yang et al.   INTERNATIONAL JOURNAL OF CANCER

Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC

(2017) Yi-Long Wu et al.   LUNG CANCER

Targeted Therapy and Immunotherapy for Lung Cancer

(2016) Evan C. Naylor et al.   Surgical Oncology Clinics of North America

Wnt Signaling Pathway in Non-Small Cell Lung Cancer

(2013) D. J. Stewart   JNCI-Journal of the National Cancer Institute